Clinical Trial

Study in Subjects With Mild-to-Moderate Alzheimer's Dementia

Active, Not Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
ALZN002-01 is a first-in-human, randomized, double-blind, placebo-controlled, parallel-group, phase 1/2a study of autologous amyloid beta mutant peptide-pulsed dendritic cells (ALZN002) in subjects with mild-to-moderate dementia of the Alzheimer's type.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2023-04-17; most recent amendment 2025-08-26.
Status change: Recruiting → Active, Not Recruiting 2024-04-11
Status change: Not Yet Recruiting → Recruiting 2023-07-28
Trial Details
NCT Number NCT05834296
Lead Sponsor Alzamend Neuro, Inc.
Collaborators: bioRASI, LLC
Conditions Alzheimer Disease
Enrollment 30 participants
Start Date 2023-07-05
Primary Completion 2028-03-03 (estimated)
Study Completion 2028-03-03 (estimated)
Updated on ClinicalTrials.gov 2025-09-02